NAD+ Boosters
NR vs. NMN
Two small human comparisons disagree on whether NR raises blood NAD+ more than NMN. Neither has shown broad health benefits or any effect on lifespan.
NR and NMN are the two best-known NAD+ supplements, and their makers and fans have spent years arguing over which one works better. It has some of the energy of a sibling rivalry, which fits: chemically, the two are next-door neighbors. If you’re comparing NR vs. NMN, Humanic Blue starts with the first trial to put both in the same room; the recent evidence is less dramatic than the debate.
The short version, then the details. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are closely related vitamin B3 derivatives that the body can use to make NAD+, a molecule involved in cellular energy and DNA repair. Two 2026 human comparisons reached different blood-marker results. A 14-day trial found that 1,000 mg/day of either precursor roughly doubled whole-blood NAD+ by similar amounts. A very small crossover study, in which each person tried both products, using 1,200 mg/day found a roughly 2.3-fold larger blood-NAD increase with NR, but no difference in brain NAD. Neither study tested whether one improves health or lifespan. Broader trials have not established meaningful muscle, metabolic, cognitive or physical-function benefits for aging adults. For living longer and better, there is no clinical-outcome basis to call either precursor superior.
Key Takeaways
- Both NR and NMN raise blood NAD+, but two small direct comparisons disagree about their relative blood effect.
- NR has more and longer human trials; NMN’s are newer.
- Neither improved muscle mass or strength in pooled trials of older adults.
- NR didn’t improve the body’s response to insulin in a 12-week trial in men with obesity.
- Neither has been shown to extend human lifespan.
The two side by side
| NR (nicotinamide riboside) | NMN (nicotinamide mononucleotide) | |
|---|---|---|
| What it is | A vitamin B3 form that cells convert to NMN, then NAD+ | The next step on the same route to NAD+ |
| Blood NAD+ effect | Raises NAD+; similar to NMN in one short trial, larger in a much smaller crossover study | Raises NAD+; similar to NR in one short trial, smaller in a much smaller crossover study |
| Longest trials | Months, in several populations, including Parkinson’s | Mostly 2 weeks to 6 months |
| Outcome results | No clear improvement in insulin response, muscle outcomes or the main thinking-test outcome in a 2026 pilot; exploratory mild clinical improvement in Parkinson’s recipients whose brain NAD+ rose | No clear improvement in muscle, blood sugar or blood fats in pooled trials; no hearing or physical-performance benefit in a new older-adult trial |
| US regulatory history | Not part of the FDA’s NMN dispute | FDA excluded it in 2022, then concluded in 2025 that it was not categorically excluded |
| The catch | Much of the field has ties to one NR manufacturer | Trials are small, short and often company-linked |
How do NR and NMN compare on NAD+?
NMN is one step closer to NAD+ than NR, which led to years of claims that one should work better or enter cells differently. A 2026 trial in Nature Metabolism compared both precursors directly. Nestlé Research scientists randomized healthy adults aged 18–50 to NR, NMN, nicotinamide or placebo for 14 days.
At 1,000 mg/day, NR and NMN each roughly doubled whole-blood NAD+ compared with placebo, with no significant difference reported between them; 500 mg/day of nicotinamide did not produce the same sustained effect. The researchers proposed that gut bacteria convert NR and NMN into nicotinic acid, but that pathway was supported partly by fermentation experiments outside the body rather than directly demonstrated as the sole mechanism in participants. Most authors were Nestlé employees, and the trial was open-label, short and limited to biomarkers.
A second 2026 phase I study complicates the comparison. A handful of healthy adults received 1,200 mg/day of NR and NMN for eight days each in a randomized crossover design. NR produced a roughly 2.3-fold larger increase in whole-blood NAD+, even after accounting for molecular weight, while brain NAD changes did not differ. With so few participants, no placebo in this stage and a focus on how the body processes the compounds rather than health outcomes, it cannot establish clinical superiority. Taken together, both precursors raise blood NAD+, while the size of the blood response varies by study design and population.
What can a short comparison of blood NAD+ establish about NR versus NMN?
Has NR improved health outcomes?
Healthy older adults. In a 2018 crossover trial at the University of Colorado Boulder, six weeks of 1,000 mg/day NR increased NAD-related metabolites and was generally well tolerated in healthy adults aged 55–79. The trial was small and aimed mainly at safety and whether NR raised NAD+; findings about blood pressure and blood-vessel stiffness were exploratory.
Metabolism. In a 12-week Danish trial, men aged 40 to 70 with obesity and insulin resistance took 2,000 mg of NR a day or placebo. The researchers concluded that NR appeared safe but did not improve insulin sensitivity or whole-body glucose metabolism. Body composition and fat burning didn’t change either.
Cognition. A 2026 phase II pilot randomized adults aged 65 or older with amnestic mild cognitive impairment, meaning mild thinking difficulties involving memory, to 1,000 mg/day of NR or placebo for 12 weeks. NR roughly doubled blood NAD+ and was well tolerated but did not significantly improve the primary cognitive outcome, whole-brain blood flow or cardiovascular function. As a small pilot without biological tests confirming Alzheimer’s-related changes, it was not a definitive dementia-prevention trial. Niagen Bioscience supplied NR and placebo but, according to the paper, had no other involvement.
Parkinson’s disease. In the phase 1 NADPARK trial in Norway, newly diagnosed patients took 1,000 mg of NR or placebo for 30 days. Brain NAD+ rose by varying amounts. Among NR recipients whose brain NAD+ increased, altered brain metabolism was associated with mild clinical improvement. This exploratory association in a small early trial does not establish a treatment benefit across all participants. Two authors filed a patent application on NR for Parkinson’s. The subsequent NOPARK phase II trial planned about 400 participants, 1,000 mg/day and 52 weeks. It completed follow-up in June 2025, but as of September 29, 2026, ClinicalTrials.gov still lists no posted results.
NMN: newer trials, similar results
NMN’s human evidence is covered in detail in NMN for Longevity. In brief, trials of 250 to 2,000 mg a day for up to 24 weeks found that it raised blood NAD+ and was generally tolerated. A 2026 meta-analysis found no effect on weight, blood sugar, HbA1c (average blood sugar over roughly three months), blood fats or systolic blood pressure (the top number). A newly published 24-week trial in adults aged 65 or older found that 1,250 mg/day raised circulating NAD-related metabolites but did not improve hearing or physical performance.
What do pooled trials say about both?
A 2025 meta-analysis of trials in adults with a mean age of 60.9 to 83 examined both precursors. NMN had no significant effect on muscle mass, grip strength, gait speed or chair-stand time. For NR, walking distance improved in people with peripheral artery disease, which restricts blood flow to the limbs, but people with mild cognitive impairment scored lower on some physical tests. The authors concluded that the current evidence does not support taking NMN or NR to preserve muscle mass and function in adults whose average age is over 60.
A 2026 systematic review of 33 human studies reached a similar conclusion for NAD+ boosters generally: clear effects on NAD+ levels, but inconsistent and often absent functional or metabolic effects.
How would the population studied change the meaning of a reported physical-function benefit?
The conflicts problem
Both supplements carry a commercial backdrop. The larger head-to-head trial came from Nestlé, and the NR used in the smaller crossover and cognitive studies was supplied by ChromaDex/Niagen Bioscience. Several prominent NAD+ researchers have disclosed NR-industry ties. NMN trials have included authors employed by NMN producers, including the new older-adult trial. None of this makes a result wrong; it raises the value of independent replication.
What’s Interesting
For years, the NR vs. NMN argument focused on which molecule reaches cells best. The 2026 head-to-head trial suggests the answer may partly run through the gut, with bacteria converting both into nicotinic acid, an older and cheaper form of vitamin B3. If that holds up, the debate over which precursor is superior may matter less than whether raising NAD+ does anything useful at all. That would be a very gut-bacteria way to end a years-long argument: quietly, and without taking sides.
What This Means in Practice
For living longer and better, neither NR nor NMN has outcome evidence to recommend it over the other, or over not taking either.
- The blood-marker comparison is unsettled. The two direct comparisons disagree, and neither tested better health outcomes.
- Blood markers and benefits differ. Trials repeatedly found higher blood NAD+; that is not a guaranteed individual response or a demonstrated health benefit.
- Purity is a separate question. Third-party testing of identity and purity does not establish effectiveness.
- Ask a clinician before starting, especially if you have cancer, liver disease, take several medications or are pregnant.
- Watch for peer-reviewed or registry NOPARK results if Parkinson’s disease is your concern, and don’t self-treat Parkinson’s with supplements.
Who was studied matters here as well. The head-to-head trial enrolled healthy adults for a short stretch, the Danish trial enrolled men with obesity and insulin resistance, and in the pooled review NR’s results split by condition, with people who had peripheral artery disease and people with mild cognitive impairment moving in different directions. The same supplement can look different depending on who takes it.
A primary care clinician or pharmacist can check for interactions. A neurologist can advise on Parkinson’s trials.
The broader product category, including what oral precursors can and cannot claim, is covered in NAD+ Supplements.
Bottom Line
NR and NMN are closely related vitamin B3 derivatives that raise blood NAD+. The larger 2026 comparison found similar blood effects; a second, much smaller crossover study found a larger NR response but no difference in brain NAD. Neither comparison measured health benefits. NR has more trials, including a completed phase II Parkinson’s study without posted results, while a new NMN trial in older adults did not improve hearing or physical performance. Much of the research carries commercial ties, and neither precursor has been shown to extend human lifespan. The more important question remains whether raising NAD+ improves health at all.
A NOTE FROM LONGEVITY365
We read research, consult expert perspectives and work to make complicated health information easier to understand. What you’re reading here reflects how we’ve interpreted and organized that information. It is educational content—not personal medical advice, diagnosis or treatment guidance.
We’re not perfect, and neither is the available research. Evidence changes, new studies emerge and what’s appropriate for one person may not be appropriate for another.
Use this article as a starting point for your own research and conversations with qualified professionals. Always talk with your doctor or another trusted healthcare professional before making decisions that could affect your health, particularly if you take medications, are receiving treatment, have existing health conditions, are pregnant or have other circumstances that could affect what’s appropriate for you.
Reader Questions
A few questions to carry into the comments or your next conversation. Please leave out identifying or personal medical details.
- 01What would you want to know before putting "NR vs. NMN" into the same conversation as sleep, food, movement, and medical care?
- 02Which evidence boundary stood out most: lifespan, function, symptoms, biomarkers, dose, safety, or who was actually studied?
- 03What question would help keep a supplement conversation grounded instead of turning it into a shopping list?
Extra Insights & Sources
The evidence summaries and linked sources behind this article.
What We Know
- NR and NMN both raise blood NAD+; one 65-person comparison found similar increases, while a six-person crossover found a larger NR increase in blood but not brain. Supported; relative effect unsettled.
- Both are generally well tolerated in short-term trials. Supported.
- Neither improved muscle or metabolic outcomes in pooled trials of adults. Supported (no clear effect).
What We Don’t Know
- Whether either extends human lifespan. Unknown. No trial has measured it.
- Whether NR helps Parkinson’s disease. Unknown until NOPARK results are publicly reported and reviewed.
- Whether higher blood NAD+ reaches and changes the tissues that matter most. Uncertain.
- Long-term safety beyond months. Unknown.
Sources
- Christen et al., Nature Metabolism (2026), PMID 41540253 — Four-arm randomized open-label trial: 67 healthy adults aged 18–50 were assigned to NR 1,000 mg/day, NMN 1,000 mg/day, nicotinamide 500 mg/day or placebo for 14 days; 65 correctly dosed participants were analyzed. Supports comparable roughly twofold whole-blood NAD+ increases with NR and NMN. It was short, biomarker-only and conducted mainly by Nestlé employees; the proposed gut-bacteria mechanism relies partly on experiments outside the body.
- Berven et al., iScience (2026), PMID 41858901 — Early open-label study of how the body processes the compounds; participants knew which product they received. In its randomized crossover stage, six healthy adults received NR and NMN at 1,200 mg/day for eight days each. Supports the larger blood-NAD response with NR and lack of a brain-NAD difference; the tiny sample, no placebo in this stage and biomarker purpose preclude clinical-superiority claims.
- Martens et al., Nature Communications (2018), PMID 29599478 — Six-week crossover trial of 1,000 mg/day NR in 24 healthy adults aged 55–79. Supports tolerability and changes in NAD-related substances in blood; small exploratory findings about blood vessels were not definitive clinical outcomes.
- Dollerup et al., American Journal of Clinical Nutrition (2018), PMID 29992272 — Twelve-week randomized trial of 2,000 mg/day NR in 40 men aged 40–70 with obesity and insulin resistance. Found no clear improvement in insulin response, blood-sugar processing, body composition or fat burning; population was narrow.
- Martens et al., Alzheimer’s & Dementia (2026), PMID 42478598 — Twelve-week phase II pilot that randomized 52 adults aged 65 or older with amnestic mild cognitive impairment; 42 completed. Supports a roughly twofold blood-NAD increase but no clear benefit for the main thinking-test outcome, whole-brain blood flow or cardiovascular measurements. Small sample, no biological tests confirming Alzheimer’s-related changes; Niagen supplied capsules but the paper reports no other company involvement.
- Brakedal et al., NADPARK, Cell Metabolism (2022), PMID 35235774 — Thirty-day phase I randomized trial of 1,000 mg/day NR in 30 people with newly diagnosed Parkinson’s disease. Found varying increases in brain NAD+; altered brain metabolism was associated with mild clinical improvement among NR recipients whose brain NAD+ increased, an exploratory association rather than an established treatment effect; it was small and two authors filed an NR-for-Parkinson’s patent application.
- ClinicalTrials.gov NOPARK record, NCT03568968 — Current primary registry record for the completed phase II trial: about 400 planned participants, 1,000 mg/day NR versus placebo, 52 weeks, completed June 17, 2025. As checked September 29, 2026, no results are posted; registry status cannot establish efficacy.
- Prokopidis et al., Journal of Cachexia, Sarcopenia and Muscle (2025), PMID 40275690 — Meta-analysis in older adults. Found no clear NMN benefit for muscle or physical function, with inconsistent NR results that differed by condition; based on few small trials.
- Gallagher & Emmanuel, Ageing Research Reviews (2026), PMID 41655607 — Systematic review of 33 human interventions and 80 rodent studies. Found reliable changes in NAD+ markers but inconsistent or absent benefits for physical function or metabolism and no human lifespan evidence; the studies varied widely.
- Igarashi et al., npj Aging (2026), DOI 10.1038/s41514-026-00482-7 — Twenty-four-week randomized trial in 60 adults aged 65 or older using 1,250 mg/day NMN. Found increases in NAD-related substances in blood without clear hearing or physical-performance benefits; manufacturer-funded with three company-employed authors.
- FDA NMN petition response, September 29, 2025 — Primary source for FDA’s conclusion that NMN is not excluded by the dietary-supplement drug-preclusion clause. This was not product approval or an efficacy finding, and other supplement requirements still apply.
Leave a Reply